Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5% - Should You Buy?

Key Points

• Stock up 7.5% — PHAT traded as high as $12.16 and last at $12.04 during the mid-day rally on Friday, on roughly 317,530 shares exchanged (about 74% below average daily volume).
• Q1 revenue beat and narrower losses — Phathom reported roughly $58.3M in Q1 revenue and a sharply reduced loss, supporting improving commercial traction for VOQUEZNA, while issuing FY‑2026 revenue guidance of $320M–$345M that is around consensus but relatively broad.
• Analyst sentiment broadly positive — Several firms raised price targets (e.g., Guggenheim to $25, Stifel $28) and the consensus rating is a "Moderate Buy" with a $22.50 target.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) rose 7.5% during mid-day trading on Friday . The company traded as high as $12.16 and last traded at $12.04. Approximately 317,530 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 1,202,066 shares. The stock had previously closed at $11.20.

More Phathom Pharmaceuticals News

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Q1 revenue beat and meaningful year-over-year improvement in losses: Phathom reported Q1 revenue of about $58.3M (above consensus) and a loss that narrowed sharply versus the year‑ago period, signaling improving commercial traction for VOQUEZNA. Read More.
• Positive Sentiment: Commercial visibility at a major medical meeting: Phathom will highlight VOQUEZNA (vonoprazan) at Digestive Disease Week (DDW 2026), which supports ongoing physician engagement and could drive future uptake. Read More.
• Neutral Sentiment: FY‑2026 revenue guidance provided but range is broad: Management issued revenue guidance of roughly $320M–$345M (around consensus but with a mid‑range that leaves room for execution risk), making guidance a mixed signal for near‑term expectations. Read More.
• Neutral Sentiment: Full earnings materials and management commentary available: The earnings call transcript and slide deck were posted (useful for investors wanting detail on sales trends, market access, and expense outlook). Read More.
• Negative Sentiment: Small EPS miss versus consensus: GAAP EPS missed estimates by roughly $0.01 (loss of ~$0.18 per share), a modest negative that may temper enthusiasm until sustained profitability or clearer margin trends appear. Read More.

Wall Street Analyst Weigh In

PHAT has been the subject of a number of analyst reports. Guggenheim increased their price objective on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, February 27th. Stifel Nicolaus set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Phathom Pharmaceuticals in a research note on Tuesday, April 21st. Barclays raised shares of Phathom Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $16.00 to $18.00 in a research note on Friday, March 27th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $22.50.

Phathom Pharmaceuticals Trading Up 3.9%

The firm has a market capitalization of $924.17 million, a PE ratio of -3.79 and a beta of 0.61. The business's 50 day simple moving average is $11.52 and its 200 day simple moving average is $13.42.

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The business had revenue of $57.58 million during the quarter, compared to analysts' expectations of $57.44 million. Analysts forecast that Phathom Pharmaceuticals, Inc. will post -0.12 earnings per share for the current year.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new stake in Phathom Pharmaceuticals in the 4th quarter valued at about $27,000. Jones Financial Companies Lllp raised its stake in shares of Phathom Pharmaceuticals by 442.6% during the third quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company's stock valued at $30,000 after acquiring an additional 2,058 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Phathom Pharmaceuticals during the second quarter valued at approximately $30,000. Summit Securities Group LLC bought a new stake in shares of Phathom Pharmaceuticals during the first quarter valued at approximately $34,000. Finally, Kestra Advisory Services LLC bought a new stake in shares of Phathom Pharmaceuticals during the fourth quarter valued at approximately $38,000. Institutional investors own 99.01% of the company's stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom's research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company's lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.